Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Summary

To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of adult patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model.

Timeline

Start

2023-01-15

Primary completion

2024-10-10

Completion

2024-12-01

Publications

• Chen J, Cao Y, Feng Y, Qi S, Yang D, Hu Y, Pang A, Shen Q, Luo J, Gong X, Zhang R, Zhai X, Li X, Yan W, Zhang X, Chen M, Niu M, Wei J, Liang C, Zhai W, Zhao N, Liu X, Liu S, Zhai W, Li R, Shao X, Zhang D, Wang M, Pan P, Xu M, Zhang W, Xu Y, Zhu X, Guo Y, Wang H, Song Z, Gale RP, Han M, Feng S, Jiang E. Autonomous artificial intelligence prescribing a drug to prevent severe acute graft-versus-host disease in HLA-haploidentical transplants. Nat Commun. 2025 Sep 25;16(1):8391. doi: 10.1038/s41467-025-62926-0.

Drugs

Indications